Tilray Brands, Inc. (TLRY)
USD 0.46
(-21.23%)
USD 0.46
(-21.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 4.33 Billion USD | -1.99% |
| 2023 | 4.3 Billion USD | -20.96% |
| 2022 | 5.44 Billion USD | -9.55% |
| 2021 | 6.02 Billion USD | 234.51% |
| 2020 | 1.8 Billion CAD | -0.19% |
| 2019 | 1.8 Billion CAD | 77.08% |
| 2018 | 1.01 Billion CAD | 334.5% |
| 2017 | 234.54 Million CAD | 743.18% |
| 2016 | 27.81 Million CAD | 141.87% |
| 2015 | 11.5 Million CAD | 3974.25% |
| 2014 | 282.27 Thousand CAD | -18.0% |
| 2013 | 344.22 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 4.33 Billion USD | -1.63% |
| 2024 FY | 4.33 Billion USD | 0.65% |
| 2024 Q4 | 4.33 Billion USD | 2.91% |
| 2024 Q1 | 4.4 Billion USD | 2.21% |
| 2024 Q3 | 4.21 Billion USD | -2.72% |
| 2023 Q3 | 4.37 Billion USD | -20.07% |
| 2023 Q1 | 5.59 Billion USD | 2.62% |
| 2023 Q2 | 5.47 Billion USD | -2.11% |
| 2023 Q4 | 4.3 Billion USD | -1.57% |
| 2023 FY | 4.3 Billion USD | -20.96% |
| 2022 Q2 | 5.76 Billion USD | -3.72% |
| 2022 Q4 | 5.44 Billion USD | -6.35% |
| 2022 FY | 5.44 Billion USD | -9.55% |
| 2022 Q1 | 5.98 Billion USD | -0.65% |
| 2022 Q3 | 5.81 Billion USD | 0.97% |
| 2021 Q2 | 2.16 Billion CAD | 13.71% |
| 2021 Q1 | 1.9 Billion CAD | 5.69% |
| 2021 Q3 | 2.2 Billion CAD | 1.7% |
| 2021 FY | 6.02 Billion USD | 234.51% |
| 2021 Q4 | 6.02 Billion USD | 173.68% |
| 2020 Q2 | 1.87 Billion CAD | 2.87% |
| 2020 Q3 | 1.94 Billion CAD | 3.7% |
| 2020 Q4 | 1.8 Billion CAD | -7.26% |
| 2020 Q1 | 1.82 Billion CAD | 0.9% |
| 2020 FY | 1.8 Billion CAD | -0.19% |
| 2019 Q4 | 1.8 Billion CAD | 15.58% |
| 2019 FY | 1.8 Billion CAD | 77.08% |
| 2019 Q2 | 1.58 Billion CAD | 26.26% |
| 2019 Q3 | 1.56 Billion CAD | -1.21% |
| 2019 Q1 | 1.25 Billion CAD | 22.83% |
| 2018 FY | 1.01 Billion CAD | 334.5% |
| 2018 Q3 | 668.99 Million CAD | 95.84% |
| 2018 Q4 | 1.01 Billion CAD | 52.33% |
| 2018 Q2 | 341.59 Million CAD | 30.23% |
| 2018 Q1 | 262.3 Million CAD | 11.84% |
| 2017 Q3 | 153.81 Million CAD | 48.98% |
| 2017 Q1 | 63 Million CAD | 126.5% |
| 2017 Q2 | 103.24 Million CAD | 63.87% |
| 2017 Q4 | 234.54 Million CAD | 52.48% |
| 2017 FY | 234.54 Million CAD | 743.18% |
| 2016 Q1 | 10.95 Million CAD | -4.73% |
| 2016 Q2 | 10.75 Million CAD | -1.88% |
| 2016 Q4 | 27.81 Million CAD | 28.78% |
| 2016 FY | 27.81 Million CAD | 141.87% |
| 2016 Q3 | 21.59 Million CAD | 100.93% |
| 2015 Q3 | 11.58 Million CAD | 7369.4% |
| 2015 Q2 | 155.08 Thousand CAD | -8.43% |
| 2015 Q1 | 169.35 Thousand CAD | -32.28% |
| 2015 FY | 11.5 Million CAD | 3974.25% |
| 2015 Q4 | 11.5 Million CAD | -0.72% |
| 2014 Q4 | 250.06 Thousand CAD | 0.79% |
| 2014 Q3 | 248.09 Thousand CAD | -9.38% |
| 2014 Q2 | 273.76 Thousand CAD | -3.01% |
| 2014 Q1 | 282.27 Thousand CAD | -2.28% |
| 2014 FY | 282.27 Thousand CAD | -18.0% |
| 2013 Q1 | 344.22 Thousand CAD | -1.39% |
| 2013 Q4 | 288.86 Thousand CAD | -5.84% |
| 2013 FY | 344.22 Thousand CAD | 0.0% |
| 2013 Q3 | 306.77 Thousand CAD | -10.91% |
| 2013 Q2 | 344.34 Thousand CAD | 0.03% |
| 2012 Q2 | 141.7 Thousand CAD | 0.0% |
| 2012 Q3 | 366.96 Thousand CAD | 158.96% |
| 2012 Q4 | 349.07 Thousand CAD | -4.88% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -5541.316% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -379.344% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -7450.411% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | -175.364% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -15752.932% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -15752.932% |
| SCYNEXIS, Inc. | 128.41 Million USD | -3276.082% |
| Safety Shot Inc | 12.7 Million USD | -34011.524% |
| Alpha Teknova, Inc. | 128.58 Million USD | -3271.488% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -279.189% |
| Bright Green Corporation | 17.4 Million USD | -24811.126% |
| Dynavax Technologies Corporation | 997.09 Million USD | -334.792% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -2006.598% |
| Cosmos Health Inc. | 66.29 Million USD | -6439.343% |
| PainReform Ltd. | 9.93 Million USD | -43558.56% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -18645.554% |
| Embecta Corp. | 1.21 Billion USD | -256.991% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -495.266% |
| Procaps Group, S.A. | 460.18 Million USD | -842.072% |
| Theratechnologies Inc. | 77.76 Million USD | -5474.58% |
| Harrow Health, Inc. | 311.75 Million USD | -1290.61% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -29009.615% |
| Biofrontera Inc. | 27.93 Million USD | -15420.89% |
| DURECT Corporation | 45.18 Million USD | -9493.695% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -207.691% |
| Cronos Group Inc. | 1.13 Billion USD | -282.216% |
| OptiNose, Inc. | 107.72 Million USD | -3924.26% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -820.302% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -7648.655% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -18710.559% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -842.404% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -36275.488% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -5201.422% |
| Radius Health, Inc. | 1.71 Billion USD | -152.647% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -8035.741% |
| ProPhase Labs, Inc. | 91.92 Million USD | -4616.019% |
| Phibro Animal Health Corporation | 982.18 Million USD | -341.393% |
| Procaps Group S.A. | 460.18 Million USD | -842.072% |
| Alvotech | 950.09 Million USD | -356.304% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -9910.148% |
| Viatris Inc. | 47.68 Billion USD | 90.909% |
| Rockwell Medical, Inc. | 52.17 Million USD | -8209.461% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -3571.023% |
| SIGA Technologies, Inc. | 254.83 Million USD | -1601.209% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -1483.947% |
| Shineco, Inc. | 84.17 Million USD | -5050.068% |
| PetIQ, Inc. | 868.22 Million USD | -399.328% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -51276.945% |
| Incannex Healthcare Limited | 17.04 Million USD | -25331.425% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -33.336% |
| Alimera Sciences, Inc. | 153.52 Million USD | -2723.855% |
| Silver Spike Investment Corp. | 88.57 Million USD | -4794.42% |
| Assertio Holdings, Inc. | 286.41 Million USD | -1413.62% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -72740.848% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -12727.912% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -13776.052% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -32625.288% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -1560.231% |
| Hempacco Co., Inc. | 18.04 Million USD | -23927.466% |
| Talphera, Inc. | 20.39 Million USD | -21156.656% |
| Alvotech | 950.09 Million USD | -356.304% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -967.386% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | -162.562% |
| Currenc Group, Inc. | 141.49 Million USD | -2964.02% |
| Kamada Ltd. | 351.96 Million USD | -1131.724% |
| Indivior PLC | 1.95 Billion USD | -122.181% |
| Evoke Pharma, Inc. | 7.06 Million USD | -61232.203% |
| Flora Growth Corp. | 23.62 Million USD | -18249.678% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -32625.288% |
| Evolus, Inc. | 188.99 Million USD | -2193.831% |
| HUTCHMED (China) Limited | 1.27 Billion USD | -238.755% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | -186.553% |
| Akanda Corp. | 8.83 Million USD | -48941.837% |